Results 21 to 30 of about 4,490 (182)

Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review [PDF]

, 2023
Entrectinib, a multikinase inhibitor of ROS1 and tropomyosin receptor kinases, is recommended to treat ROS1-positive metastatic non-small cell lung cancer (NSCLC).
Yamamoto, Takanori, Katsuki Ito, Atsushi Numaguchi, Hashimoto, Takahiko, Tetsunari Hase, Futamura, Keisuke, Sakai, Yoshinori, Futoshi Ushijima, Takanori Yamamoto, Makoto Ishii, Shotaro Okachi, Ito, Katsuki, Hirofumi Shibata, Kuniya Nakashima, Nakashima, Kuniya, Ishii, Makoto, Yoshinori Sakai, Tanaka, Akihito, Okachi, Shotaro, Ushijima, Futoshi, Shibata, Hirofumi, Takahiko Hashimoto, Yasuya Inden, Numaguchi, Atsushi, Akihito Tanaka, Hase, Tetsunari, Inden, Yasuya, Keisuke Futamura   +27 more
core   +1 more source

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

Respirology Case Reports, 2021
Chromosomal rearrangements involving the c‐ros oncogene 1 (ROS1) are identified in approximately 1% of non‐small cell lung cancer (NSCLC) patients. Crizotinib is the first tyrosine kinase inhibitor (TKI) against ROS1‐rearranged NSCLC. G2032R, a secondary
Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda   +7 more
doaj   +1 more source

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

npj Precision Oncology, 2023
Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic
Katherine Priest, Anh Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell, Kurtis D. Davies, Carolyn Lawrence, Emily O’Donnell, Robert C. Doebele, Liming Bao, Dara L. Aisner, Erin L. Schenk   +12 more
doaj   +1 more source

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

Biomedicines, 2023
The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits.
Valerio Liguori, Mario Gaio, Alessia Zinzi, Cecilia Cagnotta, Consiglia Riccardi, Giovanni Docimo, Annalisa Capuano   +6 more
doaj   +1 more source

Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date

Hematology/Oncology and Stem Cell Therapy, 2021
ROS proto-oncogene 1 (ROSI) encodes a type I integral membrane protein with tyrosine kinase activity and whose activating alterations are involved in the aggressiveness of several tumor types.
Jhajaira M. Araujo, Andrea C. Gomez, Joseph A. Pinto, Christian Rolfo, Luis E. Raez   +4 more
doaj   +1 more source

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

, 2022
The Entrectinib in NTRK+ Solid Tumours and ROS1+ NSCLC Adis Drug Evaluation video abstract, script and image slide deck provide a brief overview of the mechanism of action of entrectinib in NTRK+ solid tumours and ROS1+ NSCLC, the administration regimen ...
James E. Frampton (4995257)
core   +1 more source

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Frontiers in Oncology, 2022
Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors.
Chiara Lazzari, Lorenza Pecciarini, Claudio Doglioni, Federica Pedica, Ana Maria Samanes Gajate, Alessandra Bulotta, Vanesa Gregorc, Maria Giulia Cangi   +7 more
doaj   +1 more source

Data_Sheet_1_Inhibition of planktonic growth and biofilm formation of Staphylococcus aureus by entrectinib through disrupting the cell membrane.PDF

, 2023
Over the last few decades, Staphylococcus aureus infection remain a major medical challenge and health concern worldwide. Biofilm formation and antibiotic resistance caused by S.
Shanghong Liu (14348712), Zhijian Yu (778086), Duoyun Li (6380954), Yanpeng Xiong (9984512), Jinxin Zheng (6380957), Haitao Xiao (492387), Qiwen Deng (530955), Zewen Wen (8887517)   +7 more
core   +1 more source

Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring

Separations, 2023
Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK). It is used in the treatment of solid tumors in NTRK gene fusion lung cancer. The study aimed to develop and validate an analytical method for quantifying entrectinib
Essam A. Ali, Muzaffar Iqbal, Gamal A. E. Mostafa, Rashad Al Salahi   +3 more
doaj   +1 more source

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

, 2021
Acknowledgments During the peer review process, the manufacturer of entrectinib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
James E. Frampton (4995257)
core   +1 more source